EA001066B1 - Терапевтическое средство против астмы - Google Patents
Терапевтическое средство против астмы Download PDFInfo
- Publication number
- EA001066B1 EA001066B1 EA199800658A EA199800658A EA001066B1 EA 001066 B1 EA001066 B1 EA 001066B1 EA 199800658 A EA199800658 A EA 199800658A EA 199800658 A EA199800658 A EA 199800658A EA 001066 B1 EA001066 B1 EA 001066B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- asthma
- atom
- use according
- hydrogen atom
- Prior art date
Links
- 239000000924 antiasthmatic agent Substances 0.000 title 1
- 229940065287 selenium compound Drugs 0.000 title 1
- 150000003343 selenium compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000006673 asthma Diseases 0.000 claims abstract description 60
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- -1 methylenedioxy group Chemical group 0.000 claims abstract description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 3
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 8
- 230000001629 suppression Effects 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- 150000003957 organoselenium compounds Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 11
- 241000700198 Cavia Species 0.000 description 10
- 210000002345 respiratory system Anatomy 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 229950010033 ebselen Drugs 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 229940125388 beta agonist Drugs 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050346 Oropharyngeal candidiasis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1184896 | 1996-01-26 | ||
| PCT/DE1997/000135 WO1997026968A2 (de) | 1996-01-26 | 1997-01-27 | Therapeutische mittel, enthaltend organische selenverbindungen gengen asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA199800658A1 EA199800658A1 (ru) | 1999-02-25 |
| EA001066B1 true EA001066B1 (ru) | 2000-10-30 |
Family
ID=11789151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199800658A EA001066B1 (ru) | 1996-01-26 | 1997-01-27 | Терапевтическое средство против астмы |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0876144B1 (cs) |
| CN (1) | CN1116876C (cs) |
| AT (1) | ATE207746T1 (cs) |
| AU (1) | AU728713B2 (cs) |
| BR (1) | BR9707303A (cs) |
| CA (1) | CA2244085C (cs) |
| CZ (1) | CZ292670B6 (cs) |
| DE (2) | DE59705183D1 (cs) |
| DK (1) | DK0876144T3 (cs) |
| EA (1) | EA001066B1 (cs) |
| ES (1) | ES2165034T3 (cs) |
| HU (1) | HUP9901639A3 (cs) |
| IL (1) | IL124006A (cs) |
| NO (1) | NO983217L (cs) |
| NZ (1) | NZ330198A (cs) |
| PL (1) | PL187620B1 (cs) |
| PT (1) | PT876144E (cs) |
| TR (1) | TR199801398T2 (cs) |
| WO (1) | WO1997026968A2 (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000016935A (ja) * | 1998-07-01 | 2000-01-18 | Dai Ichi Seiyaku Co Ltd | シクロオキシゲナーゼ阻害剤 |
| WO2000058281A1 (en) | 1999-03-31 | 2000-10-05 | Daiichi Pharmaceutical Co., Ltd. | Substrates for thioredoxin reductase |
| RU2011141794A (ru) | 2009-03-17 | 2013-04-27 | Дайити Санкио Компани, Лимитед | Амидное производное |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
| CN105622478B (zh) * | 2014-10-27 | 2017-08-25 | 中国科学院大连化学物理研究所 | 3,3‑二烷硫基‑2‑苯硒基‑2‑丙烯‑1‑酮衍生物及合成 |
| CN109627198B (zh) * | 2019-02-01 | 2020-11-10 | 河南科技大学 | 一种2-丙酮基硒基苯甲酰胺类化合物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778814A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one |
| DZ1460A1 (fr) * | 1989-11-22 | 2004-09-13 | Sod Conseils Rech Applic | Nouveaux dérivés du sélénophèn ainsi que leur procédé de préparation. |
| IT1250751B (it) * | 1991-08-02 | 1995-04-21 | Boehringer Mannheim Italia | (3h,7h)selenazolo(3,4-a|piridine con attivita' antiasmatica ed antiinfiammatoria delle vie aereea |
| JP2553434B2 (ja) * | 1992-04-28 | 1996-11-13 | 第一製薬株式会社 | 粒状製剤 |
| JPH07233056A (ja) * | 1993-09-03 | 1995-09-05 | Dai Ichi Seiyaku Co Ltd | リポキシゲナーゼ阻害剤 |
| DE19506669A1 (de) * | 1995-02-25 | 1996-08-29 | Nattermann A & Cie | Lipoxygenasehemmer |
-
1997
- 1997-01-27 AT AT97914084T patent/ATE207746T1/de not_active IP Right Cessation
- 1997-01-27 IL IL12400697A patent/IL124006A/en not_active IP Right Cessation
- 1997-01-27 CN CN97191886A patent/CN1116876C/zh not_active Expired - Fee Related
- 1997-01-27 DE DE59705183T patent/DE59705183D1/de not_active Expired - Lifetime
- 1997-01-27 HU HU9901639A patent/HUP9901639A3/hu unknown
- 1997-01-27 DE DE19780042T patent/DE19780042D2/de not_active Ceased
- 1997-01-27 EA EA199800658A patent/EA001066B1/ru not_active IP Right Cessation
- 1997-01-27 DK DK97914084T patent/DK0876144T3/da active
- 1997-01-27 CZ CZ19982356A patent/CZ292670B6/cs not_active IP Right Cessation
- 1997-01-27 CA CA002244085A patent/CA2244085C/en not_active Expired - Fee Related
- 1997-01-27 TR TR1998/01398T patent/TR199801398T2/xx unknown
- 1997-01-27 PT PT97914084T patent/PT876144E/pt unknown
- 1997-01-27 EP EP97914084A patent/EP0876144B1/de not_active Expired - Lifetime
- 1997-01-27 WO PCT/DE1997/000135 patent/WO1997026968A2/de not_active Ceased
- 1997-01-27 ES ES97914084T patent/ES2165034T3/es not_active Expired - Lifetime
- 1997-01-27 BR BR9707303-2A patent/BR9707303A/pt not_active Application Discontinuation
- 1997-01-27 PL PL97328198A patent/PL187620B1/pl not_active IP Right Cessation
- 1997-01-27 NZ NZ330198A patent/NZ330198A/en unknown
- 1997-01-27 AU AU21497/97A patent/AU728713B2/en not_active Ceased
-
1998
- 1998-07-13 NO NO983217A patent/NO983217L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL187620B1 (pl) | 2004-08-31 |
| HUP9901639A1 (hu) | 1999-09-28 |
| BR9707303A (pt) | 2000-05-02 |
| AU728713B2 (en) | 2001-01-18 |
| HUP9901639A3 (en) | 2000-10-30 |
| CN1219127A (zh) | 1999-06-09 |
| ATE207746T1 (de) | 2001-11-15 |
| CA2244085A1 (en) | 1997-07-31 |
| WO1997026968A2 (de) | 1997-07-31 |
| NO983217L (no) | 1998-09-25 |
| ES2165034T3 (es) | 2002-03-01 |
| NZ330198A (en) | 2000-06-23 |
| PL328198A1 (en) | 1999-01-18 |
| TR199801398T2 (xx) | 1998-10-21 |
| CZ235698A3 (cs) | 1999-04-14 |
| NO983217D0 (no) | 1998-07-13 |
| DE59705183D1 (de) | 2001-12-06 |
| WO1997026968A3 (de) | 1997-09-25 |
| EA199800658A1 (ru) | 1999-02-25 |
| DE19780042D2 (de) | 1999-01-28 |
| PT876144E (pt) | 2002-04-29 |
| CN1116876C (zh) | 2003-08-06 |
| HK1019862A1 (en) | 2000-03-03 |
| EP0876144B1 (de) | 2001-10-31 |
| IL124006A (en) | 2004-07-25 |
| AU2149797A (en) | 1997-08-20 |
| DK0876144T3 (da) | 2002-02-25 |
| EP0876144A2 (de) | 1998-11-11 |
| CZ292670B6 (cs) | 2003-11-12 |
| CA2244085C (en) | 2008-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8318811B2 (en) | Method for treating an inflammatory bowel disease using 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or a salt thereof | |
| CA2429220C (en) | Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity | |
| JP2002537332A (ja) | 内臓痛を予防及び治療するためのガバペンチン誘導体 | |
| AU2002223514A1 (en) | Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity | |
| JP2010540607A (ja) | セチリジンと、非β２−アドレナリン受容体作動薬、β２−アドレナリン受容体作動薬、又は抗炎症薬とを含む組成物及びそれらの呼吸器疾患治療への使用法 | |
| EA001066B1 (ru) | Терапевтическое средство против астмы | |
| US6093746A (en) | Therapeutic agents for asthma | |
| CN1281361A (zh) | 芳香酶抑制剂治疗泌尿疾病的用途和研究泌尿疾病的方法 | |
| WO2021231905A1 (en) | Ketamine treatment for amyotrophic lateral sclerosis | |
| TW585763B (en) | Use of alkanoyl L-carnitines for the therapeutical treatment of chronic inflammatory bowel diseases | |
| JP4046151B2 (ja) | 喘息治療剤 | |
| RO118793B1 (ro) | Utilizarea 2-fenil-1,2-benzoizoselenazol-3()-onei pentru tratamentul astmului bronşic | |
| WO1996033741A1 (en) | Remedy for allergic diseases in the region of the nose | |
| HK1019862B (en) | Therapeutic anti-asthma agents containing selenium compounds | |
| JPS62209019A (ja) | 抗潰瘍剤 | |
| CA2353727C (en) | Use of amtolmetin guacyl for the production of anti-inflammatory drugs for intestinal inflammations | |
| JP2602701B2 (ja) | 抗アレルギー剤 | |
| Jan et al. | Comparison between the effects of extract from the seeds of Myristica fragrans and cimetidine on the volume and acidity of carbachol induced gastric secretion in fasting rabbits | |
| JPS59106419A (ja) | 消化器の炎症および潰瘍の治療剤 | |
| CA2132479A1 (en) | Pharmaceutical composition for treating or preventing allergic rhinitis | |
| JPWO2022101435A5 (cs) | ||
| MXPA01000561A (en) | Therapeutic agents for allergic diseases | |
| CZ20002138A3 (cs) | Použití inhibitorů aromatasy při léčbě sníženého poměru hladin androgenu k estrogenu a dyssynergie svalu vypuzovače a svěraěe močové trubice u člověka a způsob studia této dyssynergie u samečků hlodavců | |
| EP0526638A1 (en) | Remedy for obstructive pulmonary disease | |
| JPS63230633A (ja) | 胃腸の細胞保護剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |